{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:20:10Z","timestamp":1794500410796,"version":"4.9.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In patients with type 2 diabetes (T2D) and a history of heart failure (HF), sodium\u2013glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated cardiovascular (CV) benefits. However, the comparative efficacy of individual SGLT2is remains uncertain. This network meta-analysis (NMA) compared the efficacy and safety of five SGLT2is (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin) on CV outcomes in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched up to September 23, 2022, to identify all randomized controlled trials (RCTs) comparing SGLT2is to placebo in T2D patients with HF. The main outcomes included composite CV death\/heart failure hospitalization (HFH), HFH, CV death, all-cause mortality, and adverse events. Pairwise and NMA approaches were applied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our analysis included 11 RCTs with a total of 20,438 patients with T2D and HF. All SGLT2is significantly reduced HFH compared to standard of care (SoC) alone. \u201cAdd-on\u201d SGLT2is, except ertugliflozin, significantly reduced composite CV death\/HFH relative to SoC alone. Moreover, canagliflozin had lower composite CV death\/HFH compared to dapagliflozin. Based on the surface under the cumulative ranking curve (SUCRA), the top-ranked SGLT2is for reducing HFH were canagliflozin (95.5%), sotagliflozin (66.0%), and empagliflozin (57.2%). Head-to-head comparisons found no significant differences between individual SGLT2is in reducing CV death. \u201cAdd-on\u201d SGLT2is reduced all-cause mortality compared with SoC alone, although only dapagliflozin was statistically significant. No SGLT2is were significantly associated with serious adverse events. A sensitivity analysis focusing on HF-specific trials found that dapagliflozin, empagliflozin, and sotagliflozin significantly reduced composite CV death\/HFH, consistent with the main analysis. However, no significant differences were identified from their head-to-head comparisons in the NMA. The SUCRA indicated that sotagliflozin had the highest probability of reducing composite CV death\/HFH (97.6%), followed by empagliflozin (58.4%) and dapagliflozin (44.0%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SGLT2is significantly reduce the composite CV death\/HFH outcome. Among them, canagliflozin may be considered the preferred treatment for patients with diabetes and a history of heart failure, but it may also be associated with an increased risk of any adverse events compared to other SGLT2is. However, a sensitivity analysis focusing on HF-specific trials identified sotagliflozin as the most likely agent to reduce CV death\/HFH, followed by empagliflozin and dapagliflozin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>, identifier CRD42022353754.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1216160","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T08:48:56Z","timestamp":1703062136000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Tanawan","family":"Kongmalai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phorntida","family":"Hadnorntun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattara","family":"Leelahavarong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinkawas","family":"Kongmalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varalak","family":"Srinonprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srisakul","family":"Chirakarnjanakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usa","family":"Chaikledkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"B3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12933-021-01408-1","article-title":"Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management","volume":"20","author":"Ceriello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"d4169","DOI":"10.1136\/bmj.d4169","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diseases8020014","article-title":"SGLT2 inhibitors: the star in the treatment of type 2 diabetes","volume":"8","author":"Saisho","year":"2020","journal-title":"Diseases"},{"key":"B7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1093\/eurheartj\/ehab670","article-title":"Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S172353","article-title":"Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes","volume":"11","author":"Papakitsou","year":"2019","journal-title":"Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13300-020-00951-6","article-title":"Sodium-glucose co-transporter 2 (SGLT2) inhibitors: are they all the same? A narrative review of cardiovascular outcome trials","volume":"12","author":"Williams","year":"2021","journal-title":"Diabetes Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009099","article-title":"Out-of-pocket costs for SGLT-2 (Sodium-glucose transport protein-2) inhibitors in the United States","volume":"15","author":"Aggarwal","year":"2022","journal-title":"Circ Heart Fail"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program","volume":"138","author":"Radholm","year":"2018","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab189","article-title":"Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"29","author":"Tsampasian","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.604250","article-title":"Sodium glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13805","article-title":"Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis","volume":"9","author":"Pandey","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001099","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated systematic review and meta-analysis of 13 randomized clinical trials including 14,618 patients with heart failure","volume":"78","author":"Shrestha","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7326\/M21-0651","article-title":"Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: A randomized trial","volume":"174","author":"Szarek","year":"2021","journal-title":"Ann Intern Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1002\/ehf2.12891","article-title":"Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME","volume":"7","author":"Pellicori","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-21-0030","article-title":"Effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin for heart failure with preserved ejection fraction in patients with type 2 diabetes","volume":"3","author":"Ueda","year":"2021","journal-title":"Circ Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.750","article-title":"Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals\u2019 preferences","volume":"9","author":"Dankers","year":"2021","journal-title":"Pharmacol Res Perspective"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-021-01913-z","article-title":"Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis","volume":"111","author":"Tager","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12933-020-01141-1","article-title":"Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure","volume":"19","author":"Sayour","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1959","article-title":"Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: A subanalysis of the EMPA-REG OUTCOME trial","volume":"42","author":"Verma","year":"2019","journal-title":"Diabetes Care"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz294","article-title":"The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial","volume":"35","author":"Opingari","year":"2020","journal-title":"Nephrol Dial Transplant"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1216160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T08:48:59Z","timestamp":1703062139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1216160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":48,"alternative-id":["10.3389\/fendo.2023.1216160"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1216160","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fendo.2023.1216160.s001","asserted-by":"subject"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"article-number":"1216160"}}